Law360, New York (July 06, 2009, 12:00 AM ET) -- In the latest chapter in its long-running fight to block generic competition for the popular antidepressant Effexor XR, Wyeth has slapped Orchid Chemicals & Pharmaceuticals Ltd. and subsidiary Orgenus Pharma Inc. with a patent infringement lawsuit.
The suit, filed Thursday in the U.S. District Court for the District of New Jersey, was triggered by Orchid's abbreviated new drug application filing with the U.S. Food and Drug Administration for the manufacture, use and sale of venlafaxine HCl extended release capsules in 37.5 mg, 75 mg and 150...
Wyeth Heads To Court Again To Protect Effexor
To view the full article, take a free trial now.
